genentech setback view temporary genentech suffer temporary setback follow agency decision withhold recommendation geneticallyproduced drug treat heart attack progress industry source analyst tpa drug scene project time scale approval milstein scientist industry consultant delay arise likelihood drug approve prior initial projection add friday advisory committee food drug administration fda withhold recommendation genentech tissue plasminogen activator drug call activase athough support genentech claim drug dissolve blood clot fda data treatment benefit heartattack victim talk fda soon specifically look genentech spokeswoman company data improvement heart muscle drug administer include fda file industry analyst drop company stock expect light speculative nature biotechnology company fortune depend success drug larger pharmaceutical company product overall significance genentech robert riley senior consultant arthur little estimate genentech dollar drug delay enter market catch genentech lead industry source kabivitrum alliance hoechst hfagf recommendation streptokinase drug genentech application delay streptokinase enzymebased drug treat heart attack victim addition milstein beecham plc bhaml drug call eminase competitor tpa clinical standpoint nearly identical beecham drug approve germany await approval uk add streptokinase difficult administer heart attack victim dissolve reach heart method involve pump drug directly heart tube prove difficult heart attack progress tpa see savior easier administer quickly development streptokinase effective easier administer become potential threat genentech grasp tpa market biotech company quickly develop tpa genentech path genentech advantage market industry consultant scott formerly analyst montgomery security san francisco approve competition company patent pressure drug currently court beecham uk patent dispute patent pending analyst expect company suit soon patent issue potentially harmful situation temporary setback fda 
